AEON Biopharma, Inc. Financing Cash Flow
AEON Biopharma, Inc. (AEON) reported Financing Cash Flow of $6.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- AEON Biopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $886.00K, a 954.76% increase year-over-year.
- AEON Biopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $5.87M, a 67.99% decline year-over-year.
- AEON Biopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.79M, a 1746.39% increase year-over-year.
- AEON Biopharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $84.00K, a 68.00% increase year-over-year.
- AEON Biopharma, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $20.30M, a 34.05% increase from fiscal 2024.
- AEON Biopharma, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $15.15M.
- AEON Biopharma, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $40.51M, a 85.43% decline from fiscal 2021.
- AEON Biopharma, Inc. net cash provided by (used in) financing activities for fiscal 2021 was $277.99M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 7 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $886.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $6.76M 10-Q · filed 2026-08-12 | $8.55M derived: sum of 3 quarters · filed 2026-08-12 | $8.63M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $5.87M 10-Q · filed 2026-05-14 | $7.66M derived: sum of 2 quarters · filed 2026-05-14 | $7.75M derived: sum of 3 quarters · filed 2026-05-14 | $7.83M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.88M derived: sum of 2 quarters · filed 2026-03-30 | $1.96M derived: sum of 3 quarters · filed 2026-08-12 | $20.30M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $84.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $168.00K derived: sum of 2 quarters · filed 2026-08-12 | $18.51M 10-Q · filed 2025-11-14 | $18.61M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $18.43M 10-Q · filed 2026-08-12 | $18.53M derived: sum of 3 quarters · filed 2026-08-12 | $18.58M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $18.35M 10-Q · filed 2026-05-14 | $18.44M derived: sum of 2 quarters · filed 2026-05-14 | $18.49M derived: sum of 3 quarters · filed 2026-05-14 | $28.49M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $147.00K derived: sum of 2 quarters · filed 2026-03-30 | $10.15M derived: sum of 3 quarters · filed 2026-03-30 | $15.15M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $10.05M derived: sum of 2 quarters · filed 2025-11-14 | $15.05M 10-Q · filed 2025-11-14 | |||||
| 2024-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $15.00M 10-Q · filed 2025-08-12 | ||||||
| 2024-03-31 | $5.00M 10-Q · filed 2025-05-14 | |||||||
| 2023-07-21 | $14.00M 10-K · filed 2025-03-24 | |||||||
| 2023-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $14.00M 10-Q · filed 2024-08-12 | -$258.15M 10-Q · filed 2023-07-21 | $10.01M derived: sum of 3 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $6.00M 10-Q · filed 2024-05-14 | -$259.00M 10-Q · filed 2023-05-17 | $2.01M derived: sum of 2 quarters · filed 2024-05-14 | |||||
| 2022-12-31 | -$3.99M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-05-14 | $40.51M 10-K/A · filed 2024-05-14 | $150.00K 10-K · filed 2023-02-22 | |||||
| 2022-09-30 | $44.50M 10-Q · filed 2023-11-13 | |||||||
| 2021-12-31 | -$3.50K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-10 | -$3.50K derived: sum of 2 quarters · filed 2023-04-10 | -$3.82K derived: sum of 3 quarters · filed 2023-04-10 | $277.99M 10-K/A · filed 2023-04-10 | ||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$322.00 derived: sum of 2 quarters · filed 2022-11-14 | $278.00M 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | -$322.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $278.00M 10-Q · filed 2022-08-12 | ||||||
| 2021-03-31 | $278.00M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |